- Home
- FVRR vs GERN Comparison
FVRR vs GERN Comparison
Compare FVRR & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FVRR
- GERN
- Stock Information
- Founded
- FVRR 2010
- GERN 1990
- Country
- FVRR Israel
- GERN United States
- Employees
- FVRR N/A
- GERN N/A
- Industry
- FVRR Business Services
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- FVRR Consumer Discretionary
- GERN Health Care
- Exchange
- FVRR Nasdaq
- GERN Nasdaq
- Market Cap
- FVRR 1.0B
- GERN 974.5M
- IPO Year
- FVRR 2019
- GERN 1996
- Fundamental
- Price
- FVRR $25.93
- GERN $1.28
- Analyst Decision
- FVRR Buy
- GERN Buy
- Analyst Count
- FVRR 11
- GERN 8
- Target Price
- FVRR $36.00
- GERN $3.71
- AVG Volume (30 Days)
- FVRR 713.1K
- GERN 9.0M
- Earning Date
- FVRR 07-30-2025
- GERN 08-07-2025
- Dividend Yield
- FVRR N/A
- GERN N/A
- EPS Growth
- FVRR 127.71
- GERN N/A
- EPS
- FVRR 0.49
- GERN N/A
- Revenue
- FVRR $405,141,000.00
- GERN $116,293,000.00
- Revenue This Year
- FVRR $13.12
- GERN $161.44
- Revenue Next Year
- FVRR $8.65
- GERN $53.06
- P/E Ratio
- FVRR $54.81
- GERN N/A
- Revenue Growth
- FVRR 10.41
- GERN 22264.04
- 52 Week Low
- FVRR $20.83
- GERN $1.17
- 52 Week High
- FVRR $36.11
- GERN $4.89
- Technical
- Relative Strength Index (RSI)
- FVRR 34.20
- GERN 42.79
- Support Level
- FVRR $26.00
- GERN $1.20
- Resistance Level
- FVRR $26.91
- GERN $1.37
- Average True Range (ATR)
- FVRR 0.82
- GERN 0.08
- MACD
- FVRR -0.01
- GERN -0.00
- Stochastic Oscillator
- FVRR 18.16
- GERN 28.39
About FVRR Fiverr International Ltd. no par value
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Wiring and Translation, and Video and Animation among others.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.